Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Immune checkpoint blockers have dramatically improved the chances of survival in patients
with metastatic cancer, but only a subset of the patients respond to treatment. Search for …

Immune cells are pivotal in cancer immunotherapy, yet their therapeutic effectiveness is
often hampered by limited tumor infiltration and inhibitory tumor microenvironments. An …

Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

Mesenchymal stromal/stem cells (MSCs) are used in many studies due to their therapeutic
potential, including their differentiative ability and immunomodulatory properties. These cells …

Currently, therapeutic methods for advanced and recurrent cervical cancer patients are
limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment …

Gynecologic cancer, which includes ovarian, cervical, endometrial, vulvar, and vaginal
cancer, is a major health concern for women all over the world. Despite the availability of …

Simple Summary Ovarian cancer (OC) is the most lethal gynecological malignancy with a
five-year survival rate of 47%, followed by cervical cancer (66%), and uterine cancer (81%) …

Immune checkpoint inhibitor (ICI) resistance demands for acquisition of novel strategies in
order to broaden the therapeutic repertoire of advanced cancers. Bispecific antibodies can …